Trial intelligence / Profile preview

LUCINDA: Leuprolide in Alzheimer's Disease

NCT03649724Phase 2

Key facts

Status: Completed
Start: Nov 2020
Primary completion: Jul 2026
Countries: 1
Sponsor: Weill Cornell Medicine

Drugs: leuprolide
Conditions: Alzheimer's disease (AD)Mild Cognitive Impairment (MCI)

Overview

Phase 2, randomised, double-blind trial in Alzheimer's disease (AD) and Mild Cognitive Impairment (MCI) comparing Placebo with Leuprolide (2 arms). Primary endpoint: Alzheimer's Disease Assessment Scale-Cognitive Subscale at 48 weeks. Started Nov 2020; status: completed.

Design

2 arms

Study design: RandomizedDouble-blind

Placebo
0.25 ml normal saline SC / 12 weeks
Leuprolide
Eligard 22.5mg SC / 12 weeks

Who it enrols

Post-menopausal women with probable AD or MCI due to AD taking a stable dose of a cholinesterase inhibitor, with a MOCA > 11 and a study partner.

Endpoints

Primary

Alzheimer's Disease Assessment Scale-Cognitive Subscale48 weeks

Secondary

Alzheimer's Disease Cooperative Study - Activities of Daily Living48 weeks
Alzheimer Disease Cooperative Study Clinical Global Impression of Change48 weeks
Repeatable Battery for the Assessment of Neuropsychological Status48 weeks
Burden Inventory48 weeks
Neuropsychiatric Inventory48 weeks
Brain Magnetic Resonance Imaging biomarkers48 weeks

Beyond the preview

Go deeper on NCT03649724.

Full results, competitive context and analysis are in the Gosset platform.

Full results & analysis

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT03649724.